GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland Sells 51,420 Shares of Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland sold 51,420 shares of the stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $94.48, for a total transaction of $4,858,161.60. Following the completion of the sale, the chief executive officer now owns 1,720 shares of the company’s stock, valued at approximately $162,505.60. The trade was a 96.76 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Katherine Stueland also recently made the following trade(s):

• On Thursday, January 2nd, Katherine Stueland sold 18,006 shares of GeneDx stock. The shares were sold at an average price of $78.18, for a total value of $1,407,709.08.
• On Monday, December 16th, Katherine Stueland sold 10,501 shares of GeneDx stock. The stock was sold at an average price of $76.75, for a total value of $805,951.75.
• On Monday, December 9th, Katherine Stueland sold 3,661 shares of GeneDx stock. The stock was sold at an average price of $76.37, for a total value of $279,590.57.
• On Monday, November 18th, Katherine Stueland sold 22,307 shares of GeneDx stock. The shares were sold at an average price of $70.34, for a total transaction of $1,569,074.38.
• On Friday, November 15th, Katherine Stueland sold 23,108 shares of GeneDx stock. The stock was sold at an average price of $70.48, for a total transaction of $1,628,651.84.
• On Tuesday, October 29th, Katherine Stueland sold 2,154 shares of GeneDx stock. The shares were sold at an average price of $66.60, for a total transaction of $143,456.40.

GeneDx Trading Down 7.4 %

WGS opened at $89.38 on Friday. GeneDx Holdings Corp. has a 52 week low of $2.85 and a 52 week high of $98.87. The company has a quick ratio of 2.27, a current ratio of 2.40 and a debt-to-equity ratio of 0.25. The business has a fifty day simple moving average of $78.01 and a 200-day simple moving average of $53.19. The firm has a market cap of $2.46 billion, a P/E ratio of -28.74 and a beta of 2.02.

GeneDx (NASDAQ:WGS) last announced its earnings results on Tuesday, October 29th. The company reported $0.04 EPS for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.25. The company had revenue of $76.90 million during the quarter, compared to analysts’ expectations of $64.98 million. GeneDx had a negative return on equity of 13.35% and a negative net margin of 31.25%. GeneDx’s revenue for the quarter was up 44.3% on a year-over-year basis. During the same period last year, the business posted ($0.82) EPS. On average, equities analysts expect that GeneDx Holdings Corp. will post -0.24 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have recently commented on WGS. The Goldman Sachs Group lifted their price target on shares of GeneDx from $54.00 to $70.00 and gave the company a “neutral” rating in a research report on Wednesday, October 30th. Wells Fargo & Company lifted their target price on GeneDx from $34.00 to $75.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 30th. Craig Hallum increased their price target on GeneDx from $70.00 to $95.00 and gave the stock a “buy” rating in a report on Wednesday, October 30th. Finally, TD Cowen boosted their price objective on shares of GeneDx from $75.00 to $118.00 and gave the company a “buy” rating in a report on Tuesday. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, GeneDx presently has a consensus rating of “Moderate Buy” and a consensus target price of $70.67.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in WGS. Acadian Asset Management LLC purchased a new position in GeneDx in the 2nd quarter valued at approximately $34,000. CWM LLC acquired a new stake in shares of GeneDx in the third quarter valued at $89,000. Verition Fund Management LLC grew its stake in GeneDx by 12.9% during the 3rd quarter. Verition Fund Management LLC now owns 25,845 shares of the company’s stock worth $1,097,000 after purchasing an additional 2,945 shares in the last quarter. American Century Companies Inc. increased its holdings in GeneDx by 36.1% during the 2nd quarter. American Century Companies Inc. now owns 17,258 shares of the company’s stock worth $451,000 after purchasing an additional 4,573 shares during the period. Finally, SG Americas Securities LLC acquired a new stake in GeneDx in the 3rd quarter valued at about $198,000. Institutional investors and hedge funds own 61.72% of the company’s stock.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.